Ninlaro 2.3 mg (Ixazomib (Ixazomib Citrate) CAPSULE) 2.3 MG

NINLARO 2.3 MG capsules contain ixazomib, a medication used in cancer treatment. This oral therapy is designed to target specific proteins in cancer cells, offering a convenient option for patients.

Strength

2.3 MG

Pack Size

Manufacturer / TM Owner

TAKEDA CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

NINLARO 2.3 MG capsules are primarily used in the treatment of multiple myeloma, a type of cancer affecting plasma cells. This medication works by inhibiting proteasome activity, which can help slow the growth of cancer cells. Patients often wonder, 'What is ixazomib used for?' and the answer lies in its role as a targeted therapy for managing this specific type of cancer.

Side Effects

Common effects of NINLARO 2.3 MG capsules may include fatigue, nausea, and diarrhea. Some patients also experience peripheral neuropathy, which can cause tingling or numbness in the hands and feet. These effects can vary in severity and may require monitoring by a healthcare professional.

Precautions & Warnings

NINLARO 2.3 MG capsules should be handled with care, as they are intended for oral use only. Patients should follow the prescribed dosage and administration instructions provided by their healthcare provider. It is important to store the medication as directed to maintain its effectiveness.

Avoid Interactions

NINLARO 2.3 MG capsules may interact with certain medications, including those that affect liver enzymes. Patients should inform their healthcare provider about all medications they are taking to avoid potential interactions. Alcohol and other substances may also affect the way this medication works.

References

Frequently Asked Questions

NINLARO 2.3 MG capsules are used in the treatment of multiple myeloma, a type of cancer affecting plasma cells.

NINLARO 2.3 MG capsules are taken orally, typically once per week. Follow your healthcare provider's instructions for the best results.

Common side effects may include fatigue, nausea, diarrhea, and peripheral neuropathy. Always consult your healthcare provider for personalized advice.

It is advisable to avoid alcohol while taking NINLARO 2.3 MG capsules, as it may interact with the medication.

Store NINLARO 2.3 MG capsules at room temperature, away from moisture and heat, and keep them out of reach of children.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.